National database on RBC antibodies: why and how do we need it?

BeQuinT working group immunohaematology





Symposium 14/12/2023



Structural: legislative & financial

BeQuinT multi-annual plan

Data collection & analysis:

- National database RBC antibodies
- PBM survey
- PBM indicators
- Passerelle audit PBM hip surgery

Education

Guidance & support





Working group immunohaematology Project 1 – national database RBC antibodies

Co-chairs (clin. biologists)

- E. Lazarova (Fr)
- S. De Bruyne (NI)

Clinical biologists

- V. Deneys (Fr)
- A. Devey (Fr)
- H. El Kenz (Fr)
- A. Hendrickx (NI)
- L. Moreno (Fr)
- R. Seghaye (Fr)
- K. Van Poucke (NI)
- A. Nijs (NI)

Blood establishments:

- S. Van Landeghem (NI)
- A. Muylaert (NI)
- M.-P. Rodenbach (Fr)
- G. Bulliard (Fr)

Business analyst:

F. Dépelchin (Fr)






RBC ANTIGENS AND ANTIBODIES

- Blood group antigen –a sugar or protein present on the surface of the RBC; defined serologically by reagent antisera that react with the antigen and cause red cell agglutination
- Every blood group antigen belongs to a blood group system
- A total of 343 red cell antigens are recognized by the International Society for Blood Transfusion

Major types of RBC blood group antigens and their relationship to the RBC membrane



The three major types of RBC blood group antigens are illustrated, showing their structure and interaction with the plasma membrane. Blue denotes protein; green, sugars; and yellow, GPI. The dark blue protein covalently linked to Kell is the XK protein, required for Kell expression. Refer to UpToDate content on RBC antigens for further information and clinical relevance.


N: protein amino terminus; C: protein carboxyl terminus; GPI: glycophosphatidylinositol; RBC: red blood cell.

Modified from: The Blood Group Antigen FactsBook. Reid ME, Lomas-Francis C (Eds),
Academic Press Harcourt Brace & Co, 1997.





RBC ANTIGENS AND ANTIBODIES



- ABO system is the most important in transfusion, followed by RH system and Kell system
- Other blood group systems are also important but less frequently



SETTINGS IN WHICH BLOOD GROUPS PLAY A ROLE

- Transfusion
- Organ/tissue transplantation
- Evaluation of transfusion reaction (esp. hemolytic TR)
- Determining the risk of hemolytic disease of the fetus and newborn

Transfusion-associated hemolytic anemias






RBC ANTIGENS AND ANTIBODIES IN BLOOD COMPONENT TRANSFUSION

- Safe transfusion of RBCs : donor RBC are selected for their **compatibility** with the recipient's blood type
- Transfused RBC units do not need to be phenotypically **identical** to the recipient's RBCs, but they do need **to lack antigens** that could provoke clinically significant **hemolysis** in the recipient (eg, a blood group A donor unit cannot be transfused to a blood group O recipient, natural Ab)
- If **alloantibody** is developed to an RBC antigen (immune antibody), it is important <u>to avoid</u> <u>transfusing RBCs with that specific antigen, indefinitely</u> (importance of historical Ab)
- How an alloantibody is developed:
 - Previous transfusions
 - Pregnancy
 - Transplantation
- 20% to 80% of RBC antibodies disappear over time and can escape from detection
 - antibody specificity
 - sensitivity of laboratory techniques
 - time period after immunization






ANTIBODY DISAPPEARANCE








WHY WE NEED IT?






WHY WE NEED IT?





SITUATION "AS IS"







WHY WE NEED IT?









Additional safety benefits

e.g. extra blood group confirmation



IMPORTANT FEATURES

- ✓ a simple database where our data are stored, can be accessed and uploaded
- ✓ an application for the integration in the lab/blood bank information system of Belgian hospitals
 - "Write once, read many"; growing history
 - Limited number of "readers"; professionals who can upload data
 - Continuous availability 24/7
 - Privacy issues due to GDPR




WHAT SHOULD BE REGISTERED?



- RBC antigens
- Antibodies
 against RBC
 antigens (incl
 auto-Ab)









- Transfusions (date, product)
- Tfn reactions
- Intra-uterine tfn













WHAT ARE THE OPTIONS?





WHAT ARE THE OPTIONS?




~1000 evanescences reported over 10 years

~ 1000 potential transfusion reactions prevented over 10 years


TR!X

INFRASTRUCTURE





WHAT ARE THE OPTIONS?





HOW TO BUILD IT?

- 1. Government approval and support: September 2022
- 2. Realising « business analysis »: February 2023-November 2023
 - a) High level design solution
 - b) Project "work breakdown structure"
 - c) Estimated costs
- 3. Software development: to be started
- 4. Data exports and analyses: to be started
- 5. Implementation in Belgian hospitals: to be started





REQUIREMENTS

- Data to be exchanged: Q1 2023
 - usefulness / needs / standardization
- Expectations and requirements regarding the interface: Q3 2023
 - performances
 - visual representation
 - functionalities
- Degree of integration with the lab information system (LIS) and blood bank information system (BIS): ongoing
 - + data of blood donors from the blood establishments?



BUSINESS ANALYSIS

- LIS in Belgian hospitals Q3 2023
 - methods to encode and electronically communicate data
- eHealth standards to be met
 - healthcare provider and the patient
 - security of data
 - application of LOINC, HL7 (CDA, FHIR), SNOMED CT
- Alternatives for the target solution
 - Stand alone application



AREAS OF CONCERN

Q1: Resources for LIS development/implementation

> Hospital directory boards need to invest resources

Q2: Accessibility of data (restriction based on therapeutic relationship)? (legal cell, FPS of Public Health)

- > laboratory testing as care/therapeutic relationship;
- > responsibility for sharing a results/report

Q3: Data flows to be used? (duplication of information, other uses)

Q4: Target solution: consistent with all eHealth projects; timing and implementation challenge



OPTIONS

Option 1: Dedicated BeQuinT database and interface

- ⇒ in parallel with the main lab report publication flow?
- ⇒ procedures relevant for transfusions (but not only)

Option 2: Dedicated BeQuinT application using data directly from structured lab reports

- ⇒ Parameter: not limited to blood test (e.g. procedures)
- ⇒ Patient information without publishing a report (e.g. add a risk or a procedure directly in the health record)

Option 3: Interface with consolidated parameters of the health record in shared data vaults

⇒ Avoid duplication of data in vault and in reports



TAKE HOME MESSAGES

- National register: we definitely need it!
- Work has started
- Functional target solution
- Information standardization and share
- Governmental support

